Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, reported positive data from a recently completed clinical trial and mechanistic study of LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2 (SGLT1 and SGLT2).  The favorable safety profile and effects on multiple parameters of glycemic control and cardiovascular health in healthy normal subjects support the broad potential of LX4211 in the treatment of diabetes and associated metabolic conditions.

"Newly observed in this study were the effects of LX4211, in healthy volunteers, of decreasing postprandial glucose levels without hypoglycemia and substantially reducing triglycerides," said Brian Zambrowicz, Ph.D., executive vice president and chief scientific officer.  "Notably, the magnitudes of the reductions in triglycerides were similar to current standard of care prescription and clinical-stage medicines. By contrast, reported results of SGLT2-selective compounds have demonstrated minimal or no reductions in postprandial glucose in healthy subjects and minimal or no triglyceride decreases in either healthy normal volunteers or patients with type 2 diabetes."

Results from the study demonstrated that the 400 mg solid oral dose of LX4211 compared to placebo significantly reduced mean changes from baseline in fasting plasma glucose (p=0.005) and post-prandial glucose levels (p<0.001) in parallel with meaningful mean increases from baseline in total and active GLP-1 (p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).  GLP-1 is associated with improved glucose control and decreased food intake through reduction of appetite.  PYY is a gas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  CytRx Corporation (NASDAQ: ... development company specializing in oncology, today announced an ... lead drug candidate, aldoxorubicin.  The presentation, titled, "Drug ... will be given by Sant P. Chawla ... Center and principal investigator of the Company,s ongoing ...
(Date:10/30/2014)... Extensiv hydrolysierte Milch ... Kuhmilchverträglichkeit     Kuhmilchproteinallergie (KMPA) ist die ... Kleinkindern. Der bisher übliche Umgang mit dieser ... bzw. deren stillenden Mütter Milchproteine zu vermeiden. ... einer beträchtlichen Anzahl von Kindern der Aufbau ...
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
Breaking Medicine Technology:CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 2CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 3CytRx Announces Oral Presentation at 2014 Chemotherapy Foundation Symposium 4Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 2Experten präsentieren neuste Forschungsergebnisse auf dem Allergy Day 3Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3
... 2011 Aethlon Medical, Inc. (OTCBB: ... to address infectious disease and cancer, announces that ... a company overview, discuss recent developments and review ... & Medical Technologies Virtual Conference.   ...
... June 7, 2011 CMR Institute , the leading ... announces the addition of two new e-modules to help representatives ... (ACA): The Affordable Care ... Accountable Care Organizations and Future Healthcare Delivery ...
Cached Medicine Technology:Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 2Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16 3CMR Institute Adds e-Modules Addressing Healthcare Reform's Impact on Pharmaceutical Industry 2
(Date:10/30/2014)... Dr. Joseph Furlin MD, a certified obstetrician and gynecologist, has ... GYN in Melrose Park, IL and OB GYN ... about each of the care services and practice areas that ... and Spanish. The navigation of the website is easy ... Dr. Furlin’s patients with important information regarding his care methods ...
(Date:10/30/2014)... 2014 USARAD Holdings Inc ... and specialty telemedicine solutions provider, including SecondOpinions.com ... existing teleradiology services at Mission Bend ER, it ... telemedicine services, to the state-of-the-art, 24/7, freestanding ER ... of this innovative partnership, there will be many ...
(Date:10/30/2014)... 2014 The annual meeting of ... a close on Saturday, October 18th, marking the end ... in 1989. NAMS is North America’s leading non-profit organization ... of all women during midlife and beyond through an ... physicians and thought leaders from fields as varied as ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- When it comes ... likely than men to delay care when they have symptoms ... someone comes to the hospital with a more severe or ... options available," study author Catherine Kreatsoulas, a Fulbright Scholar and ... in a news release from the Heart and Stroke Foundation ...
(Date:10/30/2014)... Dennis Thompson HealthDay Reporter ... of milk could be bad for your health, a new ... in milk can help strengthen bones and prevent osteoporosis. These ... recommend milk as part of a healthy diet. But ... did not protect men or women from bone fractures, and ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3
... taking too much supplemental calcium are on the rise, ... of the Journal of the American Society Nephrology ... calcium-alkali syndrome is growing in large part because of ... The milk-alkali syndrome arose in the early 1900s ...
... rural southern Asia are exposed every day to unsafe levels ... doubles their risks for cancer, causes cardiovascular disease, and inhibits ... The World Health Organization (WHO) has referred to the situation ... as "the largest mass poisoning of a population in history." ...
... Experts are now recommending that low-dose aspirin therapy to prevent ... younger than 50 and women younger than 60, who have ... aspirin. The new recommendations are based on an analysis ... side effects such as stomach bleeding, and to a much ...
... found if young adults were more fit, 34% of high ... (HealthDay News) -- Low levels of physical activity and fitness ... 20-year study of young adults shows. , The study, released ... print issue of the journal Hypertension , found that ...
... to play in disease detection , TUESDAY, June 1 (HealthDay ... signs of prostate cancer in human urine, adding to the ... friend. , Some scientists have questioned similar reports of dogs ... lead author of this latest study said the findings are ...
... patients who,ve been told to rest and avoid exercise can ... both during and after treatment, according to new national guidelines. ... Biostatistics and a member of the Abramson Cancer Center at ... guidelines at an educational session at the 2010 meeting of ...
Cached Medicine News:Health News:Calcium supplements: too much of a good thing? 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 2Health News:Researchers offer solutions to poisonous well-water crisis in southern Asia 3Health News:Aspirin recommendations changed for many younger diabetic patients 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Dog Sniffs Out Prostate Cancer in Small Study 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 2Health News:New cancer guidelines: Exercise during and after treatment is now encouraged 3
... EBV laboratory diagnosis is generally confirmed by a ... the disease however, is not indicated by the ... in 10 - 20 percent of children. ... necessary to fully ascertain the stage of EBV ...
... Bard® Biopsy Instrument and Needle is specially ... goal: a large quality, reliable core sample. ... featuring ultra-sharp tips and polished surfaces for ... of biopsy systems and needle sizes assures ...
... to bring efficiency and quality to routine ... superior technology of fluorescent flow cytometry with ... sampling or batch processing are easily accommodated ... in high volume laboratories. Fluorescent flow ...
... The IsoSleeve™ Source Delivery System incorporates ... design that provides the confidence that each ... prior to implant. Unlike other preloaded needle ... verification of the loading configuration giving you ...
Medicine Products: